Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis : Episode 2

How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

July 9, 2024

Opinion

Video

Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.

EP: 1.Symptoms, Manifestations and Mortality Rate of IPF

Now Viewing

EP: 2.How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP: 3.Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP: 4.Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

EP: 5.Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis

EP: 6.Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

EP: 7.Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

EP: 8.The Roles of Biomarker Testing and HRCT in IPF and PPF

EP: 9.Unmet Needs and the Role of AI in Earlier Disease Detection

EP: 10.Adverse Events Associated with Anti-Fibrotic Therapies

EP: 11.Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

EP: 12.The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

EP: 13.K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

Video content above is prompted by the following:

How can a GAP (gender/age physiology) help determine patient prognosis with IPF or PPF?
What are the risk factors for developing IPF or PPF and can patients be screened for the disease?

Related Content

K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

MHE Staff

October 4th 2024

Article

Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.